Preclinical refers to the stage of medical research where a drug, treatment, or device is tested in the laboratory and in animals before it is ever tried in humans. It’s the critical safety checkpoint between discovering a promising compound and giving it to the first volunteer in a clinical trial. The preclinical phase typically lasts about two and a half years and exists for one reason: to find out whether something is too dangerous to test in people.
What Happens During Preclinical Research
Preclinical research answers a basic but high-stakes question: could this drug cause serious harm? To find out, researchers run two main types of tests. The first is in vitro testing, which means experiments done outside a living body, usually in test tubes, petri dishes, or cell cultures grown in a lab. These tests can reveal whether a compound is toxic to cells, damages genetic material, or interferes with blood components.
The second type is in vivo testing, which means experiments conducted in living animals. Animal studies measure how a drug affects major organ systems, including the heart, lungs, kidneys, and brain. Researchers track what dose causes problems, which organs are most vulnerable, and whether any damage reverses after the drug is stopped. They also study how the body absorbs, distributes, and clears the compound, since a drug that lingers too long or concentrates in the wrong tissue can be dangerous even at a low dose.
These studies are small compared to later human trials, but the data they produce is detailed. By the end of preclinical testing, researchers need to know three things: a safe starting dose for humans, which organs might be at risk, and what warning signs doctors should monitor for once human testing begins.
Why It Matters for Drug Development
Preclinical research is the gateway to human testing, and most drug candidates never make it through. In oncology, for example, only about 24% of drugs that enter preclinical development successfully reach a Phase 1 clinical trial, where the first small group of people receives the drug. The rest are abandoned because they prove too toxic, don’t work as expected in living systems, or can’t be manufactured reliably.
To move forward, a drug developer must submit an Investigational New Drug (IND) application to the FDA. This application has three main components: the animal safety and toxicity data from preclinical studies, detailed manufacturing information showing the drug can be produced consistently, and a protocol for the proposed human trial. The FDA review team has 30 days to evaluate the submission and either approve the start of clinical trials or place a hold on the investigation.
The preclinical stage accounts for roughly 7% of a drug’s total development cost when you only count direct expenses. But when you factor in all the compounds that fail during this phase, that share jumps to about 27% of total spending. Add in the cost of capital tied up during those years and it reaches 40%. This reflects the reality that for every drug that advances, several others were tested and discarded.
Preclinical vs. Clinical: The Key Differences
The simplest distinction is the subject. Preclinical research uses lab tests and animals. Clinical research uses people. But the goals also shift. Preclinical work asks “is this safe enough to try?” while clinical trials ask “does this actually work in humans, and what are the side effects?”
Clinical trials unfold in phases. Phase 1 enrolls 20 to 100 volunteers and focuses on safety and dosing. Phase 2 expands to several hundred patients with the target disease and measures whether the drug actually helps. Phase 3 involves 300 to 3,000 patients and confirms effectiveness while monitoring for rare adverse reactions. No drug reaches any of these stages without first clearing preclinical testing.
Quality Standards That Govern the Work
Preclinical safety studies must follow Good Laboratory Practice, or GLP, a set of federal regulations outlined in the FDA’s code. GLP isn’t a suggestion. It’s a quality system that governs how studies are designed, conducted, and documented. It covers everything from how test compounds are handled and mixed to how data is recorded and archived. The study director, quality assurance team, animal care protocols, and standard operating procedures are all subject to FDA inspection.
The purpose of GLP is to ensure that the safety data submitted to regulators is reliable and that any study could be reconstructed from its records. If a preclinical study wasn’t conducted under GLP, the FDA may not accept its results as evidence that a drug is safe enough for human trials.
Ethical Rules for Animal Testing
Because preclinical research often involves animals, it is governed by a framework known as the 3Rs: Replacement, Reduction, and Refinement. Replacement means using a non-animal alternative whenever one exists, such as cell cultures or computer models. Reduction means designing experiments to use the fewest animals possible while still producing reliable data. Refinement means minimizing pain, distress, and discomfort for any animals that are used, including improving their living conditions throughout their time in captivity.
These principles have been codified into law in the European Union through Directive 2010/63/EU and are widely adopted in regulatory frameworks around the world. There is a growing push across the research community to shift more testing from animal models to in vitro methods, which can be faster, cheaper, and in some cases more reliable. Regulators already accept in vitro tests for certain types of toxicity, though many safety assessments still require animal data.
Preclinical Testing for Medical Devices
The term “preclinical” isn’t limited to drugs. Medical devices also go through preclinical testing, though the process looks different. A new device typically starts as a prototype that undergoes bench testing (mechanical and performance evaluation in the lab) followed by animal testing to assess how the device interacts with living tissue. This cycle of testing and redesign usually takes two to three years and costs between $10 million and $20 million.
The overall timeline for bringing a device to market averages 3 to 7 years, compared to about 12 years for a new drug. Device preclinical testing focuses heavily on biocompatibility, meaning whether the materials cause irritation, allergic reactions, or toxic effects when they contact the body. The FDA requires preclinical data as part of the approval process for most devices, alongside information about how the device works, its intended use, and any known risks.